277 results on '"Omer, Bilal"'
Search Results
2. Cord blood transplantation for nonmalignant disorders: early functional immunity and high survival
3. Prolonged Cytopenias after Immune Effector Cell Therapy and Lymphodepletion in Patients with Leukemia, Lymphoma, and Solid Tumors
4. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs
5. Cell Therapy for Uveal Melanoma
6. Matched related hematopoietic cell transplant for sickle cell disease with alemtuzumab: the Texas Children’s Hospital experience
7. Reduced Cumulative Dosing of Alemtuzumab in Patients with Hemophagocytic Lymphohistiocytosis (HLH) Is Associated with Improved Long Term Survival
8. Analyzing the Effects of Obesity and Ethnicity on Outcomes of Pediatric Patients with Hematologic Malignancies Receiving Haploidentical Stem Cell Transplant with Post-Transplant Cyclophosphamide (PTCy): A Single Center Experience
9. Hematopoietic stem cell transplantation for B-thalassemia major with alemtuzumab.
10. Hematopoietic stem cell transplantation for B-thalassemia major with alemtuzumab
11. 803: CARDIOTOXICITY OF IMMUNE EFFECTOR CELLULAR THERAPIES IN PEDIATRIC HEMATOLOGIC AND SOLID TUMORS
12. Constitutive Interleukin-7 Cytokine Signaling Enhances the Persistence of Epstein–Barr Virus-Specific T-Cells
13. Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients
14. “Mini” bank of only 8 donors supplies CMV-directed T cells to diverse recipients
15. Abstract 4 Excellent Event-Free-Survival and Immunoglobulin Independence for Patients with Severe Combined Immunodeficiency Transplanted with Umbilical Cord Blood Stem Cells
16. High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease
17. Current Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphocytic Leukemia: Success, Failure and Future Perspectives—A Single-Center Experience, 2008 to 2016
18. Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome
19. Supplementary Data from A Costimulatory CAR Improves TCR-based Cancer Immunotherapy
20. Data from A Costimulatory CAR Improves TCR-based Cancer Immunotherapy
21. Data from NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors
22. Supplementary Data from NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors
23. Data from Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
24. Supplemental Table 1 from Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
25. Supplemental Figure 4 from Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
26. Supplemental Figure 3 from Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
27. Supplemental Figure Legends from Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
28. Supplemental Figure 1 from Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
29. Supplemental Figure 5 from Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
30. Supplemental Figure 2 from Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
31. Supplemental Figure 6 from Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells
32. Data from T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor–Expressing T Cells
33. Supplementary figure legend from Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells
34. Supplementary Data from T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor–Expressing T Cells
35. Supplement methodology from Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells
36. Supplementary figures 1-2 from Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells
37. GD2.CAR T Cells Incorporating a Constitutively Active Interleukin-7 Signal Modulator for CNS Tumors
38. Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting
39. 2161. Posoleucel, an Allogeneic, Off-the-Shelf Multi-Virus Specific T Cell Therapy, for Severe, Drug-Refractory Viral Infections in Pediatric Patients Following HCT: Results from a Phase 2 Trial
40. LigandCD70.CAR As a Platform for Dual-Targeting CAR T Cells for Acute Myeloid Leukemia
41. Improving Semantic Concept Detection and Retrieval using Contextual Estimates.
42. Donor-derived multiple leukemia antigen–specific T-cell therapy to prevent relapse after transplant in patients with ALL
43. Long Term Follow up for the Development of Subsequent Malignancies in Patients Treated with Genetically Modified Immune Effectors
44. Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL
45. Safety and Tolerability of Administering Leukemia-Specific Donor T Cells (mLSTs) after Allogeneic Transplant to Pediatric Patients with AML/MDS
46. Phase I Trial of GD2.CAR T Cells Combined with a Novel Interleukin-7 Signal Modulator
47. A Costimulatory CAR Improves TCR-based Cancer Immunotherapy
48. Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL
49. Wormwood ( Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn’s disease – A controlled clinical trial
50. University of Central Florida at TRECVID 2008 Content Based Copy Detection and Surveillance Event Detection.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.